Krebs Biochemicals & Industries Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 180.95 million compared to INR 64.6 million a year ago. Revenue was INR 220.11 million compared to INR 96.34 million a year ago. Net loss was INR 129.41 million compared to INR 82.6 million a year ago. Basic loss per share from continuing operations was INR 6 compared to INR 4.21 a year ago. Diluted loss per share from continuing operations was INR 6 compared to INR 4.21 a year ago.
For the nine months, sales was INR 351.36 million compared to INR 255.32 million a year ago. Revenue was INR 409.09 million compared to INR 380.18 million a year ago. Net loss was INR 332.13 million compared to INR 213.72 million a year ago. Basic loss per share from continuing operations was INR 15.42 compared to INR 10.89 a year ago. Diluted loss per share from continuing operations was INR 15.42 compared to INR 10.89 a year ago.